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ABSTRACT: HPMRS or Mabry syndrome is a hetero-
geneous glycosylphosphatidylinositol (GPI) anchor defi-
ciency that is caused by an impairment of synthesis or
maturation of the GPI-anchor. The expressivity of the
clinical features in HPMRS varies from severe syndromic
forms with multiple organ malformations to mild nonsyn-
dromic intellectual disability. In about half of the patients
with the clinical diagnosis of HPMRS, pathogenic muta-
tions can be identified in the coding region in one of the
six genes, one among them is PGAP3. In this work, we
describe a screening approach with sequence specific baits
for transcripts of genes of the GPI pathway that allows
the detection of functionally relevant mutations also in-
cluding introns and the 5′ and 3′ UTR. By this means,
we also identified pathogenic noncoding mutations, which
increases the diagnostic yield for HPMRS on the basis of
intellectual disability and elevated serum alkaline phos-
phatase. In eight affected individuals from different eth-
nicities, we found seven novel pathogenic mutations in
PGAP3. Besides five missense mutations, we identified an
intronic mutation, c.558-10G>A, that causes an aberrant
splice product and a mutation in the 3′UTR, c.∗559C>T,
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that is associated with substantially lower mRNA levels.
We show that our novel screening approach is a useful
rapid detection tool for alterations in genes coding for key
components of the GPI pathway.
Hum Mutat 37:737–744, 2016. Published 2016 Wiley Periodi-
cals, Inc.∗
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INTRODUCTION
Glycosyl phosphatidylinositol (GPI) anchor deficiencies are a new
class of congenital disorders of glycosylation that present with a
broad phenotypic spectrum that is incompletely understood. The
GPI is a glycolipid that anchors more than 150 proteins to the
cell surface. At least 27 genes are involved in the biosynthesis and
transport of GPI anchored proteins and disease-causing mutations
have been described for 13 of these genes [Kinoshita et al., 2008;
Freeze et al., 2014]. Among the most common features in GPI-
anchor deficiencies are intellectual disability, and epilepsies. For
Mabry syndrome, a well-characterized subtype of GPI-anchor defi-
ciencies, an elevated serum activity of the alkaline phosphatase is an
additional characteristic diagnostic marker that initially prompted
Mabry and collaborators to postulate a separate syndrome that is
now referred to asHyperphosphatasiawithMental Retardation Syn-
drome [Mabry et al., 1970; Horn et al., 2010; Thompson et al.,
2010]. As of 2016, six subtypes of HPMRS are known (OMIM
Phenotypic Series, PS239300) and pathogenic mutations in the
genes of the GPI anchor synthesis, PIGV, PIGW, PIGY, PIGO, as well
C© 2016 The Authors. ∗∗Human Mutation published by Wiley Periodicals, Inc.
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Figure 1. Pedigrees and segregation of identified mutations. Families A, B, C, and D are of European descent, family E is Palestinian, and patient
F is from Japan. For detailed clinical information and high-resolution photographs of patients, see Supporting Information (Supp. Fig. 1–5).
as of the anchor maturation, PGAP2 (MIM #614207) and PGAP3
(MIM #615716), have been identified [Krawitz et al., 2010; Krawitz
et al., 2012; Hansen et al., 2013; Krawitz et al., 2013; Chiyonobu
et al., 2014; Howard et al., 2014; Ilkovski et al., 2015]. For GPI
biosynthesis genes, most of the reported pathogenic variants are
missense mutations, but loss of function mutations have also been
identified.However, biallelic nonsense or frameshiftmutations have
not been observed in humans so far, but have only been found in
compound heterozygous combinations with missense mutations. It
is therefore assumed that all inherited forms of GPI-anchor defi-
ciencies, IGDs, have a residual activity of GPI-anchored proteins.
This assumption is supported by studies of animal models, as mice
incapable of forming GPI-anchors are not viable [Tarutani et al.,
1997; Nozaki et al., 1999].
Besides mutations that affect the protein function directly, hy-
pomorphic mutations in the promoters for PIGM as well as PIGY
have recently been reported [Almeida et al., 2006; Ilkovski et al.,
2015]. We therefore hypothesize that some of the unsolved cases
with Mabry syndrome might also be due to a substantial reduction
in the expression of wild-type transcripts of the known genes. As a
result, we refined our GPI-gene panel screening approach to detect
affected individuals on the RNA rather than DNA level. In the cur-
rent manuscript, we present eight previously unreported patients
(Fig. 1) with Mabry syndrome carrying novel mutations in PGAP3,
a gene of the GPI-anchor maturation. The expressivity of the phe-
notype varies considerably for this cohort (Supp. Figs. S1–S5).
Material and Methods
Mutation Analysis
Genomic DNA (gDNA) was isolated from fibroblasts or blood of
all participants of this study. The Charite´ UniversityMedicine ethics
board approved this study, and we obtained informed consent from
the responsible persons (parents) on behalf of all study partici-
pants. The DNA was fragmented and a library for high-throughput
sequencing was prepared according to standard procedures. RNA
was obtained from fibroblast cultures, fragmented and reversely
transcribed into a cDNA library. gDNA and cDNA libraries were
enriched with exon-specific oligonucleotide baits as previously de-
scribed [Krawitz et al., 2013] and high-throughput sequencing was
performed on theMiSeq platform. All sequence reads were mapped
to the genomic reference GRCh37 and processed with a splice junc-
tion mapper in case of cDNA. Most reads of the correctly spliced
mRNAs were exon-spanning and fragments mapping to intronic
sequences were rare. The coverage of coding exons of all known
GPI-synthesis-related genes was above 20-fold in all analyzed sam-
ples. Sequence variants in gDNA alignments were detected accord-
ing to GATK’s best practice guidelines. All variant calls from gDNA
that are discussed in this manuscript were validated by ABI Sanger
sequencing. Differences in transcript-specific expression were con-
firmed by quantitative PCR on RNA isolated from fibroblast cul-
tures. qPCR measurements were performed in triplicates from two
biological duplicates. dCt values were normalized against GAPDH.
Primer pair sequences and qPCR settings are available upon request.
All sequence variants described in the manuscript have also been
submitted to ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) and
GeneTalk (http://gene-talk.de/target_collections/35134).
Characterization of Noncoding Mutations
Short-read fragments from high-throughput sequencing were
first mapped to the human reference genome GRCh37 with bwa-
mem, and cDNA alignments were further refined with splice junc-
tion mapper TopHat. More than 95% of the coding positions of
all known genes of the GPI-anchor synthesis pathway were cov-
ered by more than 100 independent sequences. The allele-specific
ratios for RNA-seq experiments were assessed by considering only
high-quality reads (phred>30, less than three mismatches).
Cell Culture and Flow Cytometry
Fibroblasts were obtained from deep skin biopsies, treated with
collagenase and grown in a Dulbecco’s modified Eagle’s medium
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supplemented with 10% fetal bovine serum (FBS), 1% glutamine,
1% penicillin/streptomycin, and grown in a 5% CO2 incubator.
For investigation of GPI-anchored proteins, cultured skin fibrob-
lasts derived from patient A-II-1, patient B-II-2, patient C-II-2,
and controls were removed from the dish with cold EDTA and
a cell scraper, pipetted several times to get a single cell suspen-
sion, counted,washed, and stainedwith FLAER (fluorescent-labeled
aerolysin [AF-488]) and antibodies against GPI-linked proteins
(CD55-PE, CD59-PE, CD87-APC, CD73-PE-Cy7) in phosphate-
buffered saline without calcium or magnesium and supplemented
with 2% FBS for 1 hr at room temperature. Cells were then cen-
trifuged at 300g for 3 min and washed twice in the above solution.
Labeled cells were analyzed using a CantoII flow cytometer (BD
Biosciences San Jose, CA, USA) and FlowJoTM v. 9.8.2 software.
Results
In all individuals with the minimal diagnostic criteria develop-
mental delay, intellectual disability, and elevated serum alkaline
phosphatase, we first analyzed the gDNA of GPI-anchor pathway
genes for coding mutations as previously described [Howard et al.,
2014]. At the time of writing, we have 37 individuals whomeet these
criteria in our ongoing study andwere genetically confirmed. In this
work, we focus on the molecular findings in patients from six un-
related families, who showed mutations in PGAP3 (Fig. 1). In three
of these families, the results from gDNA sequencing were inconclu-
sive as only one heterozygous coding mutation was identified that
qualified as pathogenic, based on current classifications standards.
By cDNA sequencing, we could confirm a functional impact for
additional noncoding mutations in these patients and we argue that
this extended work-up increases the diagnostic yield. Considering
all molecularly confirmed cases of Mabry syndrome in our labora-
tory over the last 5 years, PGAP3 has now become the second most
prevalent disease gene for this phenotypic series after PIGV.
All patients with genetic alterations in PGAP3 have a combi-
nation of severe global developmental delay and elevated levels of
alkaline phosphatase activity, which are the most indicative features
for HMPRS (Table 1). However, we also observe that there is some
variability within the phenotypes and we will therefore describe the
clinical features of the patients of this report in detail. Two individ-
uals started to walk at a normal age, but the others did not walk
until the age of between 3 and 7 years, and one individual was not
able to walk at all at the age of 16 years. Five individuals did not
achieve verbal communication, and three other patients used only
single words. Furthermore, six individuals developed seizures with
variable onset and severity. Muscular hypotonia was found in four
individuals. The presence of ataxia or unsteady gait was striking in
seven patients (patients of family B, C, D, E, and F).
Six patients showed particular behavioral problems. Among
them, sleep disturbance was described as most frequently reported
feature (patients A, B, E, F); one patient (D) exhibited long-
lasting episodes of hypersomnolence classified as Klein-Levine syn-
drome. Additionally, hyperactivity, autistic features, and obsessive-
compulsive disorder were documented in patients A and D. In
patient B, MRI revealed a mild brain anomaly, namely, a small
capsula interna. The siblings of family E also showed brain atrophy
of the temporal lobes. A megacisterna magna was found in patient
F. Hearing loss was documented in three individuals (patients from
family E and F).
At birth, normal growth parameters and head circumferences
were observed in all patients. During infancy and childhood, growth
parameters were found to be variable but within the normal range
in most patients. However, two individuals showed an increased
and one a decreased weight at the last physical examination. The
postnatal occipitofrontal head circumference varied between –0.4
and +3.2 SD with three affected individuals who showed macro-
cephaly. No distinct pattern of facial anomalies was present in this
cohort. But five of them showed some facial dysmorphisms com-
patible with other forms of HPMRS, such as short nose with a broad
nasal bridge and tip, as well as a thin and tented upper lip. Apart
from broad fingers and toenails in four individuals (families B, D,
E), no other anomalies of the hands and feet were found. A cleft
palate was documented in three patients (families A, D, F).
Despite a substantial clinical variability in our patient cohort, all
patients showed global developmental delay as well as hyperphos-
phatasia and thus fulfilled the criteria for Mabry syndrome.
All affected individuals were first analyzed for rare coding vari-
ants in known exons of the GPI-anchor synthesis pathway on gDNA
as previously described [Krawitz et al., 2013] or through related se-
quencing techniques. Genomic sequencing alone was able to iden-
tify the molecular cause of the disease for the affected individuals
in family D, E, and F, identifying the following homozygous or
compound heterozygous missense mutations: D-II-1: p.Ser107Leu,
p.Asp305Gly, E-II-3 and E-II-4: p.Asp282Gly, F-II-1: p.Cys171Arg,
p.Trp287Cys (Fig. 2). All these missense mutations caused the de-
creased activity of PGAP3 (Supp. Fig. S6). This finding also confirms
that biallelic missense mutations represent the most common cause
ofMabry syndrome inall knowndisease genes,PIGV,PIGO,PGAP2,
and PGAP3.
In 4/8 patients, only single heterozygousmutations could be iden-
tified, that have a detrimental effect on the protein level or its
activity (A-II-1: p.Ser107Leu, B-II-2: p.Met135Hisfs∗28, C-II-1/2:
p.Trp287Cys) (Supp. Fig. S7). As hypomorphic promotermutations
have been described in two other genes of the GPI-anchor synthesis
pathway, PIGM and PIGY, we hypothesized that the missing second
mutations could also be noncoding variants [Almeida et al., 2006;
Ilkovski et al., 2015]. In contrast to the classification of coding mu-
tations, predicting the effect of variants that are deeply intronic or
in untranslated regions (UTR) is challenging from a bioinformatics
perspective. We have therefore further developed our gene-panel
screening approach in such a way that it is suitable for the analysis
of transcripts involved in the GPI-anchor synthesis and remodeling.
Before we subjected the samples to a quantitative analysis of cDNA,
we confirmed a reduction of GPI-linker markers on the cell surface
(Fig. 3; Supp. Fig. S6).
In the subsequent analysis of the cDNA, we achieved optimal
results in target-specific enrichment with a mean fragment size
around 200 bp. Most reads of the correctly spliced mRNAs were
exon-spanning and fragments mapping to intronic sequences were
rare.
A considerable amount of sequence reads that map to intron 5
in PGAP3 were found in the affected individuals of families A and
B. In A-II-1, there is a sharp drop in coverage at the intron–exon
boundary to almost 50% and in B-II-2 to about 70%, indicating
that a heterozygous allele is causing a splicing defect. Most of the
sequence fragments that reach into intron 5 show the intronic vari-
ant c.588-10G>A, whereas this variant is a clear heterozygous call on
the genomic level (Fig. 4). In all heterozygous carriers of the c.588-
10G>Amutation as well as in all healthy controls, there is a low rate
of intron 5 fragments with the wild-type allele c.588-10G.We there-
fore assume that even in the wild type, intron 5 is not always spliced
out, but that the mutation c.588-10G>A reduces the splicing effi-
ciency dramatically. The single base pair duplication c.402dupC in
the father of the family B (B-I-1) results in a premature stop codon.
The resulting transcript including the c.402dupC is thus subject to
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Table 1. Summary of Clinical Findings in Patients Carrying PGAP3Mutations
Patient A-II-1 B-II-2 C-II-1 C-II-2 D-II-1 E-II-2 E-II-4 F-II-3
Ethnicity European
American
German French French British Palestinian Palestinian Japanese
Consanguinity No No No No No Yes Yes No
Age of last assessment
(years)
25 years 3 years 5 years 3.5 years 23 years 16 years 10 years 3 years
OFC at birth 35 cm Normal +2 SD +2 SD Normal Normal Normal Normal
OFC +3.2 SD +0.4 SD +3 SD +2 SD +1.2 SD +0.4 SD –0.4 SD Normal
Height –0.6 SD +0.4 SD Normal Normal Normal +0.4 SD + 0.4 SD –2 SD
Weight BMI 33.3 +2.4 SD Normal Normal Normal –2.4 SD –1.4 SD –2 SD
Global developmental
delay
+ + + + + + + +
Motor delay + + + + + + + +
Speech and language
development
No word Single
words
No word No word No word Single words Single words No word
Muscular hypotonia – + – – – + + +
Seizures + + + – + + + –
Age of onset of seizures
(years)
21 years 18 months 24 months NA 23 years 3½ years 5 years NA
Type of seizures Generalized,
myoclonic
Myoclonic Myoclonic Myoclonic NA Not specified Generalized,
myoclonic
NA
AEDs Lamotrigine Valproate Valproate,
diazepam
NA Levetiracetam Lamotrigine,
clonazepam
Clonazepam NA
Behavioral abnormalities Sleep distur-
bance,
autism,
aggres-
sion,
OCD
Sleep dis-
turbance
– – Autism, mood
disorder,
hypersom-
nolence
Sleep
disturbance
Sleep
disturbance
Sleep
disturbance
Other neurological
abnormalitites
– Ataxia Ataxia, ocu-
lomotor
apraxia
Ataxia Unsteady gait Ataxia,
sensorineural
hearing loss
Ataxia,
sensorineural
hearing loss
Ataxia,
sensorineural
hearing loss
Facial gestalt
Apparent hypertelorism – + – – – – – –
Upslanting palpebral
fissures
+ – – – – – – –
Broad nasal bridge + + – – + – – –
Broad nasal tip – + – – + + + –
Short nose – + – – – – – –
Tented upper lip
vermilion
+ + + + + + + –
Large, fleshy ear lobes – – – – + – – +
Cleft palate + – – – + +
Brachytelephalangy – Broad
finger
and
toenails
– – Broad second
toe nail
Broad finger
and toenails
Broad finger
and toenails
–
Serum total ALP (U/l) 469 333 830–1,000 830–900 300–738 807 633 1,848–5,275
Upper reference limit in
ALP test (U/l)
136 297 410 410 105 297 297 335
Further anomalies – Small teeth – – Constipation,
intestinal
malrotation
– – Constipation,
severe food
allergy,
eczema
PGAP3 variants
(NM 033419.3)
c.320C>T,
c.558-
10G>A
c.402dupC,
c.558-
10G>A
c.861G>T,
c.∗559C>T
c.861G>T,
c.∗559C>T
c.320C>T,
c.914A>G
c.845A>G
(hom)
c.845A>G
(hom)
c.511T>C,
c.842T>C
OFC, occipitofrontal head circumference; SD, standard deviations; BMI, body mass index; ND, no data available; NA, not applicable; OCD, obsessive compulsive disorder; ALP,
alkaline phosphatase.
nonsense-mediated decay, which is confirmed by qPCR expression
analysis of PGAP3 in fibroblasts. The second heterozygous muta-
tion of the index (B-II-2) c.588-10G>A results in an expression level
of only 10% (Supp. Fig. S8). This also explains the less prominent
reduction of coverage in B-II-2 at the exon–intron boundary (Fig.
4; panel 4).
In affected individuals C-II-1 and C-II-2, we identified a het-
erozygous missense mutation in exon 7 of PGAP3, c.861G>T,
p.Trp287Cys. The only sequence variant that would qualify as
pathogenic second PGAP3 mutation based on its allele frequency
is a novel 3′UTR mutation, c.∗559C>T. On the cDNA level, this
mutation only occurs in less than a fifth of the reads, indicating a
more than threefold reduction of this transcript (Fig. 5A). This is in
agreement with the contrary ratio of the compoundmissensemuta-
tion c.861G>T that is present in the majority of the sequence reads.
The low expression of PGAP3 for the haplotype with the 3′UTR
mutation can be quantified by qPCR from fibroblast RNA. The fa-
ther, C-I-1, who is a heterozygous carrier of the missense mutation
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Figure 2. Overview of pathogenic mutations in PGAP3. A: The coding sequence of PGAP3 is organized in eight exons. The majority of pathogenic
mutations in PGAP3 aremissensemutationswithout a specific pattern for the distribution of pathogenic variants. The intronicmutation c.558-10G>A
impairs the splicing of intron 5 and the 3′UTR mutation c.∗559C>T is associated with a reduced expression. Mutation numbering is based on cDNA
level. B: The protein has seven predicted transmembrane domains (TDs), and the mutations affect highly conserved amino acid residues in TDs as
well as in the intracellular and extracellular sites. Green: known pathogenic mutations, cyan: new pathogenic mutations.
p.Trp287Cys, shows expression levels comparable to a healthy con-
trol, whereas the index (C-II-2) and her mother (C-I-2), who are
carrier of c.∗559C>T, have amarkedly reduced expression of PGAP3
(Supp. Fig. S8).
In summary,wehave four patientswithnoncoding variants in our
cohort that are likely to retain a residual level of functional PGAP3.
However, we suspected that the amount of wild-type PGAP3 is
pathologically low and in consequence it should have the same
detrimental impact on GPI-anchored markers, GPI-APs, as seen
for pathogenic coding variants. So far, flow cytometry is used in a
qualitativemanner to assess GPI-anchor deficiencies on a functional
level. FACS analysis of the peripheral granulocytes is very helpful
in the diagnostic procedure of inherited GPI deficiencies. Many
IGD’s show decreased expression of CD16 or FLAER compared
with healthy controls. But the limitation is that the blood should be
analyzed within 2 days without fixation, otherwise the expression
levels gradually decrease, which makes the results unreliable. For
more quantitatively applicable results, we established a flow cytom-
etry protocol for fibroblasts and assessed the cell surface levels for
GPI-APs for different patients. In all three patients with noncoding
mutations in PGAP3, the mean fluorescent intensity (MFI) of the
GPI-linked proteins CD55, CD59, as well as FLAER was markedly
reduced compared with healthy controls (Fig. 3). The reduction
was similar in PGAP3 deficient fibroblasts with compound het-
erozygous mutations (QM-100:[p.Asp305Gly; p.Leu147Profs∗16])
[Howard et al., 2014].
Discussion
HPMRS represents the largest subgroup of IGDs. The clinical
variability of the expressivity of this syndrome is wide and little
is known about gene- or genotype–phenotype correlations. In our
current study group intellectual disability as well as elevated ALP
are the only consistent features across patients compared with other
individuals affected with HPMRS caused by mutations in PIGV,
PIGW, PIGY, PIGO, and PGAP2. Speech development, especially
expressive language, was more affected than motor skills in the
majority of patients (Table 1). Seizures are present in themajority of
this cohort. Behavioral problems, in particular, sleep disturbances
and autistic features as well as ataxia tend to be frequent. Most
patients of this cohort presented with some facial dysmorphism
compatible with HPMRS. Furthermore, brachytelephalangy, which
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Figure 3. Cell surface levels of GPI markers on fibroblasts. The mean
fluorescent intensity (MFI) of theGPI-anchored proteins CD55 andCD59,
as well as FLAER is significantly reduced in fibroblasts of all PGAP3 de-
ficient individuals, compared with pooled healthy controls, confirming a
GPI-anchor deficiency on a functional level. On average, the reduction
of marker expression in individuals A-II-1, B-II-2, and C-II-2 is compa-
rable with the reduction of QM-100 (compound heterozygous carrier of
two coding mutations: c.440_441insC, c.914A>G).
is an important diagnostic sign in other types of HPMRS, is not
present in any of the affected individuals with PGAP3 mutations.
Cleft palate as the only associatedmalformation found in this cohort
has been previously documented in other individuals with HPMRS
due to mutations in PGAP3 but also in the other groups of Mabry
syndrome. Variability regarding the postnatal growth, body weight,
and OFC has already been observed in individuals carrying PIGV,
PIGO, and PGAP2mutations.
For all known HPMRS disease genes, the majority of pathogenic
variants are missense mutations, a finding that is also supported
by our data. Frameshift mutations, which result most likely in a
complete loss of function, have only been observed in a compound
heterozygous state with missense mutations and individuals with
such combinations seem to be affected more severely.
Flow cytometry of GPI-anchored markers on the cell surface of
peripheral granulocytes has been used in many patients with sus-
pected IGDs for confirmatory diagnostic purposes. However, FACS
measurements on blood cells are known to be variable in time
and expression levels are difficult to compare between samples. In
a measurement of granulocytes from F-II-3, we did, for instance,
not observe a marked reduction of GPI-makers, although the mu-
tations have been shown to be pathogenic in the CHO test assay
Figure 4. Intronic mutation causing aberrant splicing. The coverage is shown for gDNA and cDNA of PGAP3 for exons 5, 6, and partly 4, as well
as for introns 4 and 5 of individuals A-II-1 (panel 1 gDNA and panel 2 cDNA), B-II-2 (panel 3 gDNA and panel 4 cDNA), and one control (panel 5
cDNA). gDNA sequence reads of the affected individuals of family A and B show the heterozygous intronic mutation c.558-10G>Awith the expected
ratio of about 50%. Intron 4 is correctly spliced out in the cDNA of all samples. A low rate of reads map into intron 5 in the healthy control (panel
5), suggesting that intron 5 is not removed in all transcripts. However, the two affected individuals show a high increase of reads from intron 5 in
the cDNA. While about half of the enriched fragments of genomic DNA show the c.558-10G>A mutation, the fraction of the mutation increases to
about four-fifth in the cDNA. The heterozygous mutation c.558-10G>A thus impedes correct splicing of intron 5 from the pre-mRNA and results in
an aberrant splice product.
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Figure 5. Effect of 3′UTR mutation on transcript level. A: The ratio of reads on gDNA of the compound heterozygous mutations c.861G>T and
c.∗559C>T are comparable (upper panel) in the affected individual from family C. For cDNA data, the allelic balance deviates in opposite directions.
On cDNA level, the ratio of the mutant allele at the 3′UTR position drops below one-fifth, whereas most of the sequence reads show the mutant
allele at the position of the missense mutation. B: Sanger sequencing of gDNA and cDNA of individual C-II-2. A quantitative measurement of
transcripts carrying the mutations is not possible via Sanger sequencing.
(Supporting Information). In other cases, repeated measurements
of ALP in the same patient have also shown values that were only
borderline high in some instances. Thus, also unremarkable results
in flow cytometry of blood cells do not rule out HPMRS (Supp.
Fig. S9).
For a better reproducibility and comparability of different
pathogenic mutations, we established a FACS protocol for fibrob-
lasts and tested cells with noncoding as well as coding mutations
in PGAP3 and PIGV. Although the numbers for which we were
able to perform FACS analysis on fibroblasts are still too small
to be statistically significant, there seems to be no obvious cor-
relation between the MFIs of the tested markers and the severity
of the phenotype. The reduction in MFI in fibroblasts with im-
paired PGAP3 is also comparable to cells with pathogenicmutations
in PIGV that we previously assessed (PIGV-X-II-1: [p.Ala341Glu;
p.Ala341Glu], PIGV-Y-II-1:[p.Ala165Glu; p.Arg460∗], PIGV-Z-II-
2: [p.Cys156Tyr; p.Ala341Glu]). In two of these patients, intellec-
tual disability is the predominant clinical feature [Krawitz et al.,
2010; Horn et al., 2011], whereas in patient PIGV-Y-II-1 (not
reported so far) the most prominent manifestation is treatment-
resistant epilepsy. Seizures are a common feature in HPMRS and
in some cases they are intractable and life-threatening [Naka-
mura et al., 2014]; PIGV-Y-II-1 thus represents a severely af-
fected case with frequent status epilepticus. Still, no quantita-
tive differences of the MFIs between the milder and more severe
PIGV cases could be observed in the fibroblast cultures (data not
shown).
Most pathogenic mutations in genes of the GPI-anchor synthesis
primarily decrease the surface expression of GPI-anchored proteins
(e.g., PIGV), whereas deficiencies in PGAP2 or PGAP3 genes, which
involve in lipid remodeling in the Golgi result in expression of GPI-
APs that are more prone to cleavage [Maeda et al., 2007]. PGAP3 is
among putative membrane-bound hydrolases called CREST super-
family proteins, and it removes unsaturated fatty acid from the sn-2
position of lipid moiety of GPI anchored protein in the Golgi, the
first step of fatty acid remodeling, followed by the attachment of sat-
urated fatty acid through PGAP2 involvement [Pei et al., 2011]. This
fatty acid remodeling reaction is necessary for association of GPI-
APs to lipid raft. In PGAP3-deficient cells, GPI-APs are expressed
at normal level but could not localize on lipid rafts because of their
non-remodeled lipid structure, whichmight cause the symptoms of
the patients.
For a better understanding of genotype–phenotype correlations
in Mabry syndrome, it might be worthwhile to extend the flow cy-
tometric profiling to more GPI-APs and to further tissues. A deeper
insight into the dynamics of GPI-APs on the cell surface might
also help us to design experiments for analyzing the conjectured
feedback mechanism that regulates the expression of genes of the
GPI-anchor synthesis.
Our study also shows that new screening approaches, such as
cDNA sequencing, will help increase the diagnostic yield for inher-
ited GPI-anchor deficiencies further. With a quantitative and allele-
specific analysis of transcripts, regulatory variants can be identified,
extending the pathogenic mutation spectrum of Mabry syndrome.
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